News Headlines

  1. Aspect Biosystems And Novo Nordisk Enter New Phase Of Partnership To Develop Curative Medicines For Diabetes 1/20/2026

    Novo Nordisk and Aspect Biosystems today announced they are entering a new phase of their partnership to develop advanced cellular medicines for diabetes.

  2. Syngene International Extends Long-Term Research Collaboration With Bristol Myers Squibb Until 2035 1/20/2026

    Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035.

  3. Genentech More Than Doubles Investment In Holly Springs, North Carolina Manufacturing Facility 1/20/2026

    Genentech, a member of the Roche Group, today announced an expansion of its initial investment in a new Holly Springs, North Carolina manufacturing facility. The increased investment will more than double the total commitment for the company’s first-ever East Coast manufacturing facility to approximately $2B.

  4. Genezen And Atsena Therapeutics Announce Strategic Commercial Manufacturing Partnership 1/20/2026

    Genezen, a leading gene therapy contract development and manufacturing organization (CDMO), and Atsena Therapeutics ("Atsena"), a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced a strategic manufacturing partnership to advance the clinical development and commercial manufacturing of Atsena's pipeline programs powered by novel adeno-associated virus (AAV) technology engineered to overcome the hurdles presented by inherited retinal diseases.

  5. Alcami Acquires RTP Facility To Further Expand Biologic Capabilities 1/19/2026

    Alcami Corporation, a leading U.S.-based contract development and manufacturing organization (CDMO), has acquired a 37,000-square-foot facility at 4620 Creekstone Drive in Durham, North Carolina. This $6.7 million investment strengthens Alcami's presence in the Research Triangle region and supports the company's continued expansion of advanced laboratory services.

  6. AbelZeta Announces Remaining China Rights To GPC3 Armored CAR-T Therapy To Be Acquired By AstraZeneca 1/18/2026

    belZeta Pharma, Inc. ("AbelZeta"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, announced that AstraZeneca has agreed to acquire AbelZeta's 50% share of the China development and commercialization rights to C-CAR031, such that AstraZeneca acquires the sole right to develop, manufacture and commercialize C-CAR031 globally.

  7. Kindeva Announces Leadership Transition To Drive Strategic Growth 1/16/2026

    Kindeva, a global contract development and manufacturing organization (CDMO) and drug delivery innovator, today announced a series of planned leadership transitions designed to position the company for accelerating growth in its core businesses focused on parenteral and inhaled drug delivery. 

  8. Wilmington PharmaTech Appoints Seasoned Commercial Leader To Drive Growth 1/16/2026

    Wilmington PharmaTech (“WPT”), a U.S.-based specialty contract research, development and manufacturing organization (CRDMO) focused on complex custom small molecule API, today announced that it has appointed Mike Shearer to the role of Chief Commercial Officer, where he will play a pivotal role in driving growth, strengthening client partnerships, and furthering the organization’s position as a trusted partner for API development and manufacturing. Shearer will report to Hui-Yin “Harry” Li, Ph.D., WPT’s Founder and CEO.

  9. 3PBIOVIAN Strengthens Its International R&D Positioning With French CIR Certification At Its Sites In Spain And Finland 1/16/2026

    3PBIOVIAN, a leading CDMO in process development and manufacturing of recombinant proteins and advanced therapies, has obtained the French CIR (Crédit d’Impôt Recherche) certification at its two production and development sites: Turku (Finland) and Pamplona (Spain). The certification is valid until 2027 and strengthens the company’s position as a strategic partner for international R&D projects.

  10. Coating Place Secures Growth Capital Investment By 1315 Capital 1/16/2026

    Coating Place, a leading U.S.-based contract development and manufacturing organization (CDMO), has secured a strategic, growth investment from 1315 Capital, a Philadelphia-based healthcare-focused private equity firm.